683 Capital Management, LLC Contrafect Corp Transaction History

683 Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.79 - $4.45 $139,500 - $222,500	50,000 Added 5.0%	1,050,000 $3.22 Million
Q4 2021 Feb 14, 2022	BUY	$2.47 - $4.14 $434,808 - $728,789	176,036 Added 21.36%	1,000,000 $2.63 Million
Q3 2021 Nov 15, 2021	BUY	$3.19 - $4.43 $519,115 - $720,902	162,732 Added 24.61%	823,964 $3.34 Million
Q2 2021 Aug 16, 2021	BUY	$3.58 - $4.9 $756,210 - $1.04 Million	211,232 Added 46.94%	661,232 $2.91 Million
Q1 2021 May 17, 2021	SELL	$4.46 - $6.68 $669,000 - $1 Million	-150,000 Reduced 25.0%	450,000 $2.16 Million
Q2 2020 Aug 14, 2020	BUY	$4.69 - $7.81 $2.26 Million - $3.77 Million	482,500 Added 410.64%	600,000 $3.83 Million
Q1 2020 May 15, 2020	BUY	$5.5 - $12.3 $646,250 - $1.45 Million	117,500 New	117,500 $676,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.